DGKA and acute myeloid leukemia: In addition, the DEGs in the DGKα high-risk group were enriched in the Jak-Stat/MAPK signaling pathway, whose activation induces partial AML production [38] and promotes tumor growth [39], and some AML patients are resistant to conventional treatment due to MAPK pathway activation [40].